Therapeutic strategies for Huntington's disease: current approaches and future direction

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Huntington's disease (HD) is a progressive, inherited neurodegenerative disorder.
• It stems from CAG trinucleotide expansion in the Huntington gene, causing toxic mutant huntingtin (mHTT) accumulation in the brain.
• HD manifests as motor, cognitive, and psychiatric impairments.

Purpose of the Study:

• To review current research on therapeutic strategies for Huntington's disease.
• To explore novel approaches including small molecules, gene therapies, and protein degradation techniques.
• To assess the potential of specific agents like VTX-003 and ANX005.

Main Methods:

• Literature review of existing research on HD therapeutic development.
• Analysis of small-molecule approaches, gene therapies (e.g., CRISPR-based), and protein degradation techniques.
• Evaluation of emerging therapies targeting mHTT reduction.

Main Results:

• Multiple therapeutic strategies show promise in reducing mHTT levels.
• CRISPR-based approaches and small-molecule targeted protein degradation are key areas of development.
• VTX-003 and ANX005 are being investigated for their potential to slow disease progression.

Conclusions:

• Significant progress has been made in developing treatments for Huntington's disease.
• Challenges remain in long-term efficacy, drug delivery, and minimizing off-target effects.
• Enhanced therapeutic interventions are crucial for improving patient quality of life.